Andrew took up leadership of Step Pharma in September 2019. Prior to joining Step, he was CSO at Zealand Pharma, Denmark. Prior experience, covering scientific strategy and business development, was garnered from leadership roles with Shire Pharmaceuticals, Opsona Therapeutics and AstraZeneca. He has also acquired venture capital experience as General Partner and Scientific Director for the Life Sciences Investment Fund Eclosion2.
Andrew was awarded a PhD in molecular biology from the National Institute for Medical Research at Mill Hill, London, which he followed with post-doctoral research at Johns Hopkins Medical School, Baltimore, USA. He has an MBA from the University of Warwick Business School, UK.
